I-MAB (IMAB) EBIT per Share : $-0.49 (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB EBIT per Share?

I-MAB's EBIT per Share for the three months ended in Dec. 2024 was $-0.15. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.49.

During the past 3 years, the average EBIT per Share Growth Rate was 47.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for I-MAB's EBIT per Share or its related term are showing as below:

IMAB' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -43.8 Med: 43.9 Max: 47.4
Current: 47.4

During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of I-MAB was 47.40% per year. The lowest was -43.80% per year. And the median was 43.90% per year.

IMAB's 3-Year EBIT Growth Rate is ranked better than
89.47% of 1235 companies
in the Biotechnology industry
Industry Median: 8 vs IMAB: 47.40

I-MAB's EBIT for the three months ended in Dec. 2024 was $-12.10 Mil.

I-MAB EBIT per Share Historical Data

The historical data trend for I-MAB's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB EBIT per Share Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT per Share

Get a 7-Day Free Trial

1.08

-4.82

-0.64

-0.57

-0.62

I-MAB Quarterly Data
	Dec17	Sep18	Dec18	Jun19	Sep19	Dec19	Jun20	Sep20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24	Dec24
EBIT per Share	Get a 7-Day Free Trial														-0.13	-0.18	-0.19	-0.15	-0.15

I-MAB EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

I-MAB's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-50.153	/	81.186
=	-0.62

I-MAB's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

	EBIT per Share		(Q: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-12.098	/	81.503
=	-0.15

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.49

I-MAB (NAS:IMAB) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

I-MAB EBIT per Share Related Terms

Thank you for viewing the detailed overview of I-MAB's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

0VY:Germany

Address

2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850

Website

https://www.i-mabbiopharma.com

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).